Watch Online the Live Sessions of ISWWTA 2015 Rishikesh on Youtube.Visit:https://www.youtube.com/user/ayushdarpan/
Previous issues of AYUSH DARPAN in Hindi is now available online visit:http://ayushdarpan.org

Search Engine

Tuesday, 6 September 2016

Edible ginger-derived nano-lipids created from a specific population of ginger nanoparticles show promise for effectively targeting and delivering chemotherapeutic drugs used to treat colon cancer, according to a study by researchers at the Institute for Biomedical Sciences at Georgia State University, the Atlanta Veterans Affairs Medical Center and Wenzhou Medical University and Southwest University in China.

Colorectal cancer is the third most common cancer among men and women in the United States, and the second-leading cause of cancer-related deaths among men and women worldwide. The incidence of colorectal cancer has increased over the last few years, with about one million new cases diagnosed annually. Non-targeted chemotherapy is the most common therapeutic strategy available for colon cancer patients, but this treatment method is unable to distinguish between cancerous and healthy cells, leading to poor therapeutic effects on tumor cells and severe toxic side effects on healthy cells. Enabling chemotherapeutic drugs to target cancer cells would be a major development in the treatment of colon cancer.

In this study, the researchers isolated a specific nanoparticle population from edible ginger (GDNP 2) and reassembled their lipids, naturally occurring molecules that include fats, to form ginger-derived nano-lipids, also known as nanovectors. To achieve accurate targeting of tumor tissues, the researchers modified the nanovectors with folic acid to create FA-modified nanovectors (FA nanovectors). Folic acid shows high-affinity binding to the folate receptors that are highly expressed on many tumors and almost undetectable on non-tumor cells.

The FA nanovectors were tested as a delivery platform for doxorubicin, a chemotherapeutic drug used to treat colon cancer. The researchers found that doxorubicin was efficiently loaded into the FA nanovectors, and the FA nanovectors were efficiently taken up by colon cancer cells, exhibited excellent biocompatibility and successfully inhibited tumor growth. Compared to a commercially available option for delivering doxorubicin, the FA nanovectors released the drug more rapidly in an acidic pH that resembled the tumor environment, suggesting this delivery strategy could decrease the severe side effects of doxorubicin. These findings were published in the journal Molecular Therapy.

"Our results show that FA nanovectors made of edible ginger-derived lipids could shift the current paradigm of drug delivery away from artificially synthesized nanoparticles toward the use of nature-derived nanovectors from edible plants," said Dr. Didier Merlin, a professor in the Institute for Biomedical Sciences at Georgia State and a Research Career Scientist at the VA Medical Center. "Because they are nontoxic and can be produced on a large scale, FA nanovectors derived from edible plants could represent one of the safest targeted therapeutic delivery platforms."

Dr. Mingzhen Zhang of the Institute for Biomedical Sciences at Georgia State is the first author of the study. Co-authors of the study include Dr. Emilie Viennois, Dr. Zhan Zhang and Moon Kwon Han of the Institute for Biomedical Sciences at Georgia State; Dr. Bo Xiao of the Institute for Biomedical Sciences at Georgia State and Southwest University in Chonqing, China; and Dr. Changlong Xu of the Institute for Biomedical Sciences at Georgia State and Wenzhou Medical University in Wenzhou, China.

The study was supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, the Department of Veterans Affairs and the Crohn's & Colitis Foundation of America.

Source:National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, the Department of Veterans Affairs and the Crohn's & Colitis Foundation of America.

OFFICIAL WEBSITES OF AYUSH DARPAN

Feedjit

E- JOURNAL OF AYUSH DARPAN

About Me

Post Graduate in Ayurvedic Medicine & Post Graduate Diploma Holder in Yogic Sciences. Started clinical carrier from 1999.Joined various Institutions for teaching Ayurvedic Graduates. Edited many Health magazines and published articles in leading Newspapers.Field of clinical speciality is Panchakarma and Yoga.Founder/ Editor of AYUSH DARPAN(ISSN.09763368/RNI No.2010/33674). Regular writer for Dainik Bhaskar Jeevan Mantra and Blog writer for Navbharat Times and Dainik Jagran.Working for giving benefits of Indian System of Medicine:-Ayurveda,Yoga and its specialty "Panchakarma and Kshar Sutra" to common peoples.Participated in approx. 1000 Medical Health Camps organised in rural areas all over India.Participation in various National and International Seminars/Workshop related with Ayurveda,Yoga,Naturopathy and Modern Medicine. Presentation and publication of various papers in Journals and Magazines.Now working in Kumaoun region of Uttarakhand. Creating awareness for endangered Himalayan Medicinal Herbs by creating Live Videos uploaded in Youtube and shown in the popular sites of Dainik Bhaskar and Navbharattimes. AYUSH DARPAN is promoting as a nonprofitable platform working for these issues.